Is IDEAYA Biosciences (IDYA) Undervalued After Its FDA Backed IDE849 Trial Plan?
IDEAYA Biosciences (IDYA) is under scrutiny after outlining an FDA-backed registrational plan for IDE849, its DLL3 targeted antibody drug conjugate. Despite a recent share price decline, Simply Wall St analysts suggest the stock is undervalued by 48% at its current price of $27.41 compared to a fair value of $52.75, based on pipeline progress and future execution risk. The company's success hinges on the execution of multiple registrational programs and managing competitive pressures in DLL3 therapies.
Ideaya Biosciences stock hits 52-week low at 26.8 USD By Investing.com
Ideaya Biosciences (IDYA) stock has dropped to a 52-week low of $26.80, representing a 17.12% decrease over the past year. Despite this, the company has a strong balance sheet with more cash than debt and is trading below its InvestingPro Fair Value of $30.23, suggesting potential for recovery. Several analysts have updated their price targets, maintaining generally optimistic ratings based on the potential approval of darovasertib.
RBC Capital maintains IDEAYA Biosciences at Outperform, keeps price target at $45
RBC Capital has reaffirmed its Outperform rating for IDEAYA Biosciences (IDYA) and maintained a price target of $45, implying a potential upside of 48.2% from its recent closing price. This follows similar positive actions from other firms like Mizuho, Citigroup, Truist Securities, and Guggenheim in the past 30 days, with price targets ranging from $39 to $66.
Ideaya plans registration trials for IDE849 in cancer treatment By Investing.com
Ideaya Biosciences Inc. announced plans to initiate registrational trials for IDE849, an antibody-drug conjugate, in neuroendocrine carcinomas and extensive-stage small cell lung cancer by year-end. The company intends to conduct a single-arm extension cohort for potential accelerated approval and a randomized Phase 3 trial for full approval, evaluating the drug at 2.4 mg/kg and 3.5 mg/kg doses. This follows promising Phase 1 results from its partner Hengrui, which showed a 52.6% overall response rate in neuroendocrine carcinoma patients.
IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas
IDEAYA Biosciences has announced a successful Type C meeting with the U.S. FDA regarding its registrational strategy for IDE849, a DLL3 TOP1 ADC, in neuroendocrine carcinomas (NEC). The company plans to initiate a single-arm extension cohort for potential accelerated approval in GEP-NEC and a randomized Phase 3 trial to support full approval across multiple NEC subtypes. This strategy is based on promising clinical data showing a 52.6% ORR and favorable safety profile for IDE849 in previously treated NEC patients.
IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors
IDEAYA Biosciences has nominated IDE101 as a development candidate, a potential first-in-class dual CDK inhibitor targeting CDKN2A-deficiency, which is prevalent in 10-15% of all solid tumors, including about 70% of pancreatic cancer. The company is advancing IND-enabling studies with plans for an IND filing in the first half of 2027. IDE101 shows promise as a monotherapy and in combination with RAS and MTAP inhibitors, including IDEAYA's proprietary PRMT5 inhibitor IDE892.
IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors
IDEAYA Biosciences has nominated IDE101 as a development candidate, a potential first-in-class dual cyclin-dependent kinase (CDK) inhibitor targeting CDKN2A-deficiency, which is prevalent in 10-15% of all solid tumors, including pancreatic cancer. Preclinical studies show promising activity for IDE101 as a monotherapy and in combination with RAS inhibitors and IDEAYA's PRMT5 inhibitor IDE892. The company is advancing IND-enabling studies with an aim to file an Investigational New Drug application with the FDA in the first half of 2027.
IDEAYA Biosciences (IDYA) Swung To A Third Quarter Loss, Is The Undervaluation Case Intact?
IDEAYA Biosciences (IDYA) reported a third-quarter loss of US$125.75 million, despite revenue of US$10.24 million, swinging from a profit last year. While Simply Wall St's analyst consensus suggests the stock is 40% undervalued with a fair value of $52.75, based on pipeline execution, their DCF model flags the stock as expensive at $31.83 compared to an estimated future cash flow value of $6.80. The company's future hinges on the successful execution of its registrational programs for darovasertib and IDE849, along with managing funding needs exacerbated by a new shelf registration.
How Investors Are Reacting To IDEAYA Biosciences (IDYA) Earnings And Drug Trial Updates
IDEAYA Biosciences reported third-quarter 2026 revenue of US$10.24 million and a net loss of US$125.75 million, alongside filing a US$94.92 million shelf registration. The company also provided updates on its darovasertib NDA submission and promising IDE849 clinical data, including a 17.4-month median overall survival in SCLC, which clarifies the drug's potential role in its portfolio. Investors are evaluating the company's ability to transition into a multi-asset oncology platform amidst significant losses and execution risks related to regulatory timelines and trial readouts.
RBC Capital maintains IDEAYA Biosciences at Outperform, lowers price target to $45 from $48
RBC Capital has reaffirmed its Outperform rating for IDEAYA Biosciences but reduced its price target to $45 from $48, a 6.2% decrease. This new target suggests a 43.6% upside from the stock's closing price of $31.33 on November 3. Recent analyst actions on IDEAYA Biosciences have seen price targets ranging from $48 to $63 over the past 30 days.
A cancer drug candidate’s human data will feature at IDEAYA’s Nov. 16 research day.
IDEAYA Biosciences (NASDAQ: IDYA) will participate in investor events on November 16 and 17, 2026, including an Investor R&D Day in London. The R&D Day on November 16 will provide a comprehensive overview of their drug candidate IDE892, including Phase 1 clinical data, RAS research, and preclinical combination strategies. The company's CEO, R&D President, and CFO will also participate in the UBS Global Biopharma Conference and the Jefferies Global Healthcare Conference.
IDEAYA Biosciences announces participation in key November investor events showcasing cancer drug progress.
IDEAYA Biosciences will participate in major investor events on November 16-17, 2026, including the UBS Global Biopharma Conference and Jefferies Global Healthcare Conference. The company will provide updates on its cancer drug candidates, such as IDE892, a PRMT5 inhibitor, and discuss clinical progress in targeting specific cancer types. Live webcasts of these events will be available for investors.
IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events
IDEAYA Biosciences, a precision medicine oncology company, announced its participation in several upcoming investor relations events in November 2026, including the UBS Global Biopharma Conference, an Investor R&D Day, and the Jefferies Global Healthcare Conference. These events will feature discussions with company leadership and provide updates on their pipeline, including clinical data for IDE892 and progress on RAS-driven cancer strategies. Advance registration is required for the Investor R&D Day, and webcasts will be available for all events.
IDEAYA Biosciences Q3 loss widens to $125.7M
IDEAYA Biosciences reported a widened net loss of $125.7 million for Q3 2026, up from $112.5 million in the previous quarter, despite an increase in collaboration revenue. The company completed its first FDA application for darovasertib and expects significant savings from closing a Phase 3 trial. IDEAYA is also advancing other clinical trials and maintains its cash runway guidance into 2030.
Truist cuts Ideaya Biosciences stock price target on revised estimates By Investing.com
Truist Securities has lowered its price target for Ideaya Biosciences (NASDAQ:IDYA) from $59 to $57, while maintaining a Buy rating. This adjustment follows the company's third-quarter results and revised estimates for darovasertib uveal melanoma revenue, along with an increased probability of success for DLL3. Ideaya is strategically focusing on higher-priority programs, supported by a strong financial position, and plans a research and development day to discuss its MTAP/CDKN2A plus RAS strategy.
Truist cuts Ideaya Biosciences stock price target on revised estimates By Investing.com
Truist Securities has lowered its price target for Ideaya Biosciences (NASDAQ: IDYA) from $59 to $57, while maintaining a Buy rating. This adjustment follows the company's third-quarter results and a meeting with management, reflecting revised estimates for darovasertib revenue and an increased probability of success for DLL3. Ideaya Biosciences plans to hold an R&D day on November 16 to discuss its MTAP/CDKN2A plus RAS strategy and is expected to release initial IDE849 data by year-end 2026 or early 2027.
IDEAYA Reports Q3 2026 Results, $1.15 Billion in Cash and Darovasertib NDA Submission
IDEAYA Biosciences (IDYA) reported a Q3 2026 net loss of $125.7 million but ended the quarter with a strong cash position of $1.15 billion, extending its cash runway into 2030. The company also announced the completion of an NDA submission for darovasertib in metastatic uveal melanoma and provided updates on its clinical pipeline, including plans for two Phase 3 trials for IDE849.
IDEAYA Biosciences Releases Q3 2026 Financial Results
IDEAYA Biosciences, Inc. reported a loss of $1.22 per share for Q3 2026, a decline from the prior year's profit, with a net loss of $125.7 million. Despite the loss, the company saw a 15.6% increase in revenue, reaching $10.2 million, driven by its pipeline of precision oncology candidates. Wall Street analysts maintain a strong "buy" consensus, indicating confidence in IDEAYA's development strategy for targeted cancer therapeutics.
Ideaya Biosciences earnings missed by $0.05, revenue topped estimates
Ideaya Biosciences reported third-quarter EPS of $-1.22, missing analyst estimates by $0.05, but exceeded revenue expectations with $10.24 million against a consensus of $6.98 million. The company's stock price closed at $31.64, showing a -12.69% decline over the last three months but a 3.81% increase over the past year. InvestingPro rated Ideaya Biosciences's financial health as "good performance."
A drug for eye melanoma showed a 57% eye-preservation rate in one trial group
IDEAYA Biosciences reported a widened net loss of $125.7 million in Q3 2026 but maintained its cash runway guidance into 2030. The company submitted its first FDA application for darovasertib plus crizotinib for metastatic uveal melanoma and presented positive clinical data, including a 57% eye preservation rate in a primary uveal melanoma trial. IDEAYA also detailed progress in its IDE849, IDE161, IDE034, IDE892, IDE397, and IDE574 pipeline programs, with several Phase 3 trials planned.
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $44
Mizuho Securities has reiterated its "Buy" rating for IDEAYA Biosciences (IDYA.US) but has lowered its price target to $44. This adjustment reflects a revised valuation perspective while still maintaining a positive outlook on the company's prospects.
IDEAYA BIOSCIENCES, INC. : MIZUHO CUTS TARGET PRICE TO $44 FROM $50
Mizuho has adjusted its target price for IDEAYA Biosciences, Inc. (IDYA) shares, reducing it to $44 from the previous $50. Despite this reduction, the firm maintains a "Buy" rating on the company's stock, indicating continued confidence in its long-term prospects.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences, a precision medicine oncology company, announced that its Compensation Committee granted non-qualified stock options for 99,600 shares to four new employees. These grants were made under the 2023 Employment Inducement Incentive Award Plan, compliant with Nasdaq Listing Rule 5635(c)(4), to attract new talent. The options have an exercise price of $32.89 per share and vest over four years, subject to continued employment.
Four new IDEAYA hires get options to buy shares at $32.89 each
IDEAYA Biosciences (NASDAQ: IDYA) has granted stock options for 99,600 shares to four new employees, with an exercise price of $32.89 per share, matching the closing price on the grant date of October 29, 2026. These awards, made under the company's 2023 Employment Inducement Incentive Award Plan, are designed to attract new talent and vest over a four-year period, contingent on continued employment. The options have a 10-year term, with 25% vesting after the first year and the remainder in monthly installments over the subsequent three years.
UBS Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50
UBS has reiterated its Buy rating for IDEAYA Biosciences (IDYA.US), maintaining a target price of $50. This indicates the firm's continued positive outlook on the company's stock performance.
ESMO26: Zai and Ideaya showcase DLL3 drugs in lung cancer
At ESMO26, Zai Lab and Ideaya presented new trial data for their DLL3-targeting drugs, zocilurtatug pelitecan (zoci) and IDE849, respectively, aiming to compete with Amgen's Imdelltra in lung cancer treatment. Zai Lab's zoci showed an 81.8% ORR in combination with Tecentriq for first-line extensive-stage small cell lung cancer (ES-SCLC), with a phase 3 trial planned. Ideaya and Hengrui's IDE849 demonstrated promising overall survival and response rates in relapsed SCLC, prompting plans for two phase 3 registration trials.
IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas
IDEAYA Biosciences announced updated Phase 1 clinical results for IDE849 (SHR-4849), an investigational antibody-drug conjugate, showing promising anti-tumor activity and preliminary overall survival (OS) in relapsed small cell lung cancer (SCLC) and neuroendocrine carcinomas (NECs). The study reported a median OS of 17.4 months in second-line SCLC and 14.7 months across all previously treated SCLC patients, with notable objective response rates. Following these positive results, IDEAYA plans to initiate two Phase 3 registrational trials for IDE849 in ES-SCLC and NEC.
IDEAYA Biosciences, Inc. Estimates – NASDAQ:IDYA
This article provides an overview of IDEAYA Biosciences, Inc. (NASDAQ: IDYA) financial data and analyst estimates available on TradingView. It directs users to explore reported financial data, compare actual results with estimates, and visualize trends across income statements, balance sheets, cash flow statements, and valuation metrics. The information is presented as a tool for research, with a disclaimer that it is not investment advice.
IDEAYA reports IDE849 trial data in lung cancer, neuroendocrine tumors By Investing.com
IDEAYA Biosciences Inc. announced updated clinical results from a Phase 1 study of IDE849, an antibody-drug conjugate targeting delta-like ligand 3, for small cell lung cancer and other neuroendocrine carcinomas. The data, presented at the European Society for Medical Oncology Congress 2026, showed promising overall survival and response rates, with manageable adverse events. IDEAYA plans to initiate two Phase 3 registrational trials for IDE849 after discussions with the U.S. FDA.
17.4 months was median survival after one prior treatment in an early small-cell lung cancer study.
IDEAYA Biosciences announced updated Phase 1 results for IDE849, an antibody-drug conjugate, showing promising anti-tumor activity and preliminary overall survival in relapsed small cell lung cancer (SCLC) and neuroendocrine carcinomas (NECs). In second-line SCLC, the median overall survival was 17.4 months. Following successful FDA meetings, IDEAYA plans to initiate two global Phase 3 trials for IDE849 in extensive-stage SCLC and NEC.
IDEAYA reports IDE849 trial data in lung cancer, neuroendocrine tumors
IDEAYA Biosciences Inc. announced updated clinical results from a Phase 1 study of IDE849, an antibody-drug conjugate targeting delta-like ligand 3, showing promising efficacy in small cell lung cancer and neuroendocrine carcinomas. The data, presented at the European Society for Medical Oncology Congress 2026, indicated significant overall response rates and median overall survival, alongside manageable treatment-related adverse events. Following these results, IDEAYA plans to initiate two Phase 3 registrational trials for extensive-stage small cell lung cancer and neuroendocrine carcinomas.
Citizens reiterates USD 42.00 target for IDEAYA Biosciences stock
Citizens has reiterated a USD 42.00 price target and Market Outperform rating for IDEAYA Biosciences (IDYA), ahead of the company's upcoming ESMO presentations and London R&D Day. Despite a widening net loss in Q2 2026, the target suggests an 18.31% upside from its recent Nasdaq price. Investors are watching the estimated earnings date on November 9, 2026, and the R&D Day on November 16, 2026, as key checkpoints for the company's pipeline and valuation.
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $48
RBC Capital has reiterated its Buy rating for IDEAYA Biosciences (IDYA.US), a biotechnology company focused on oncology. The firm has also maintained its target price for the company at $48, signaling continued confidence in its future performance and potential.
IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma
IDEAYA Biosciences and Servier presented updated clinical data from three trials (OptimUM-01, OptimUM-02, and OptimUM-09) at ESMO 2026, showcasing darovasertib's potential as a foundational therapy for uveal melanoma. The data indicated significant clinical benefits in metastatic uveal melanoma, irrespective of HLA-A*02:01 status, and robust tumor shrinkage in primary uveal melanoma, leading to increased eye preservation rates. These findings support darovasertib's broad applicability across the disease's treatment journey.
Citizens reiterates Ideaya Biosciences stock rating ahead of ESMO By Investing.com
Citizens has reiterated its "Market Outperform" rating and a $42.00 price target for Ideaya Biosciences (NASDAQ:IDYA) in anticipation of its presentations at the upcoming ESMO conference. The company is set to deliver updated data on darovasertib for uveal melanoma and Phase 1 data for IDE-849 (SHR-4849). This news comes amidst recent analyst initiations and price target adjustments from William Blair, Stifel, Cantor Fitzgerald, and Guggenheim, all pointing to potential growth for Ideaya Biosciences.
IDEAYA presents uveal melanoma trial data at ESMO 2026
IDEAYA Biosciences Inc. announced clinical trial data from three studies on darovasertib for uveal melanoma patients, presented at ESMO 2026. The OptimUM-01 Phase 2 study showed promising progression-free and overall survival rates in metastatic uveal melanoma, while OptimUM-02 demonstrated improved outcomes for darovasertib plus crizotinib. The OptimUM-09 trial highlighted significant tumor shrinkage and eye preservation in primary uveal melanoma, with IDEAYA planning to submit a new drug application in the second half of 2026.
William Blair sets USD 51.00 target for IDEAYA Biosciences stock
William Blair has initiated coverage of IDEAYA Biosciences (IDYA) with an Outperform recommendation and a USD 51.00 price target, representing a potential 55.25% upside from its October 16, 2026 Nasdaq close. The consensus target from analysts is USD 53.80. The company reported second-quarter revenue of USD 8.86 million and a GAAP net loss of USD 112.45 million, with its next earnings date scheduled for November 2, 2026.
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $48
RBC Capital has reiterated its Buy rating on IDEAYA Biosciences (IDYA.US), maintaining a target price of $48. This indicates a continued positive outlook on the company's stock performance by the firm.
William Blair Initiates Coverage on IDEAYA Biosciences With Outperform Rating
William Blair has initiated coverage on IDEAYA Biosciences (IDYA) with an Outperform rating. The company currently holds an average rating of "buy" among analysts, with a mean price target of $53.54. Access to the full MT Newswires article requires a premium subscription.
William Blair initiates Ideaya Biosciences stock with outperform rating
William Blair has initiated coverage on Ideaya Biosciences (NASDAQ: IDYA) with an outperform rating, citing the potential approval of darovasertib for metastatic uveal melanoma in the first half of 2027. The drug showed strong Phase III data, particularly for HLA-negative patients who lack other treatment options. The firm also recognized Ideaya's robust R&D capabilities and strong financial position, despite current unprofitability, with other analysts maintaining a strong buy consensus.
Stifel sets USD 48.00 target for IDEAYA Biosciences stock
Stifel has set a USD 48.00 price target for IDEAYA Biosciences (NASDAQ: IDYA) with a "Buy" rating, which is 42.35% higher than its current Nasdaq quote. The biotechnology company is scheduled to report its third-quarter results on November 9, 2026. As of October 15, 2026, IDEAYA Biosciences had a market capitalization of USD 3.3 billion, and its stock was trading at EUR 30.04 on Lang & Schwarz.
Stifel initiates Ideaya Biosciences stock with buy rating By Investing.com
Stifel has initiated coverage on Ideaya Biosciences (NASDAQ: IDYA) with a buy rating and a price target of $48.00, representing a 40% upside. The firm anticipates Ideaya transitioning to a commercial-stage company in 2027 with its lead drug, darovasertib plus crizotinib, for metastatic uveal melanoma. Analysts also highlighted further upside potential from pipeline programs and the company's strong financial position with cash runway into 2030.
IDEAYA resumed at Buy at Stifel on combo treatment for uveal melanoma (IDYA:NASDAQ)
Stifel has resumed coverage of IDEAYA Biosciences (IDYA) with a Buy rating, citing the potential for the company's darovasertib and crizotinib combination to become the standard of care for first-line metastatic uveal melanoma. The firm set a price target of $48, indicating a significant upside.
Trading the Move, Not the Narrative: (IDYA) Edition
This article provides an AI-generated analysis for Ideaya Biosciences Inc. (NASDAQ: IDYA), highlighting weak near and mid-term sentiment but a strong long-term outlook. It details specific institutional trading strategies (Long, Momentum Breakout, Short) with entry, target, and stop-loss levels, and presents a multi-timeframe signal analysis indicating support and resistance levels. The report emphasizes an exceptional short setup with a high risk-reward ratio.
Form 144 IDEAYA Biosciences For: 11 October By Investing.com
The article reports on a Form 144 filing by IDEAYA Biosciences (IDYA) for October 11. Form 144 is a notice of the intent to sell restricted securities. The brief article, published by Investing.com, indicates this financial activity for the company.
Form 144 IDEAYA Biosciences For: 11 October By Investing.com
This article reports on the filing of Form 144 for IDEAYA Biosciences (IDYA) on October 11, 2026. Form 144 indicates an intent to sell restricted securities, which can be of interest to investors tracking insider activity. The article itself is very brief, simply stating the filing and its date.
Form 144 IDEAYA Biosciences For: 11 October By Investing.com
This article announces the filing of Form 144 for IDEAYA Biosciences (IDYA) on October 11. It's a brief news item from Investing.com, indicating a regulatory filing related to the company's stock. The article provides the stock ticker and a slight decrease in its value.
Form 144 IDEAYA Biosciences For: 11 October By Investing.com
This article from Investing.com reports on a Form 144 filing for IDEAYA Biosciences (IDYA) on October 11. Form 144 is a document filed with the SEC by an affiliate of a company who intends to sell restricted securities. The brief notice indicates a transaction involving IDYA shares.
Form 4 Ideaya Biosciences Inc For: 8 October By Investing.com
This article announces the filing of a Form 4 for Ideaya Biosciences Inc. on October 8th. It appears to be a placeholder or a very brief report, indicating insider transaction activity for the company on that date. The article itself contains minimal content beyond the announcement.
Form 4 Ideaya Biosciences Inc For: 8 October By Investing.com
This article announces the filing of Form 4 for Ideaya Biosciences Inc. on October 8th. It is a brief report from Investing.com, typical of filings news. The article also contains various market data, including indices, commodities, and individual stock performances, alongside popular news headlines.